B&K CORP-B (02396) announces its annual performance, with a net loss of 2.09 billion yuan, a year-on-year decrease of 1.5%.

date
22:17 30/03/2026
avatar
GMT Eight
Huaren Biology-B (02396) released its annual results for the year ending December 31, 2025. The group achieved revenue of 522,000 yuan, an increase of 100% compared to the previous year. It incurred a loss of 209 million yuan for the year, a decrease of 1.5% compared to the previous year. Loss per share was 2.08 yuan.
B&K CORP-B(02396) announced its annual performance for the period ending on December 31, 2025. The group achieved a revenue of 522,000 yuan, an increase of 100% compared to the previous year; a loss of 209 million yuan, a decrease of 1.5% compared to the previous year; and a loss per share of 2.08 yuan. The announcement stated that the increase in revenue was mainly due to the sale of PDGF BB reagent for research and experiments to a single customer, which was a one-time sale. Providing research services and selling PDGF-BB reagent are not part of our core business.